COVID-19 Impacting Patent Litigation, From Exclusivity Forfeiture To Launch Delays

 
• By Brenda Sandburg

Pandemic poses new hurdles for Hatch-Waxman and BPCIA litigants as they navigate US FDA approval times, sponsor filing deadlines and biosimilar launch dates.

question marks judge gavel Coronavirus Covid-19 symbolic 3d-illustration
COVID-19 Raises Numerous Questions In Biopharma Patent Litigation

More from Legal & IP

More from Pink Sheet